Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2017
At a glance
- Drugs TAK 003 (Primary) ; TAK 003 (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Inviragen
- 30 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 07 Dec 2011 Results have been presented at the annual American Society of Tropical Medicine and Hygiene, according to an Inviragen media release.
- 01 Nov 2011 Status changed from active, no longer recruiting to completed.